Investor Presentation

September 2, 2026 National Stock Exchange of India Limited BSE Limited Plot No. C/1, “G” Block, Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai 400 051 Mumbai 400 001 Symbol: RPGLIFE Security Code: 532983 Dear Sirs, Sub: Investors Presentation In continuation to our letter dated September 2, 2026 informing Analyst/Institutional Investors meeting, please find enclosed herewith a copy of Investors Presentation. Kindly take the above on record. Thanking you, Yours Sincerely, For RPG Life Sciences Limited Rajesh Shirambekar Head- Legal & Company Secretary Encl: as above RPG Life Sciences RPG Active Pharma – Transaction Update 02nd September, 2026 A Subsidiarization of API business into RPGAP for strategic focus API business • The API business operates from state-of-the-art Promoters Public Shareholders facility located at Navi Mumbai • Focused on high-value low-volume niche products which ware fairly insulated from price 72.95% 27.05% commoditization and Chinese competition. • Growing product pipeline with strong R&D focus • Strong team being put into place led by CEO with deep experience at industry majors like Teva, RPGLS DRL, UPL etc. and supported by dedicated management team with CXOs having strong industry pedigree Formulations API business Business • External (third-party) sales of ~95.1 Cr INR in FY26, apart from captive sales to RPGLS for Formulations Business API Business transferred • The subsidiarization was completed via Business to RPGAP Transfer Agreement i.e. slump sale mechanism 100% • There is a Supply Services and Transition agreement towards continuing captive sales, RPGAP shared services and transition support B Partnership with pharma-centric PE firm InvAscent for value creation Invascent (Investor) • InvAscent is one of India’s most specialised pharma-centric Private Equity firm bringing in over 20 years of experience of building businesses in formulations, API, healthcare RPGLS Investor delivery, medtech, animal health and health- tech • Total AUM of USD 850 Mn+ across 4 funds 60% 40% trusted by marquee investors from across the Primary issuance globe - 40% shareholding on diluted basis • InvAscent as a partner brings in growth capital, (consideration of deep sectoral knowledge with strong industry ~243.33 Cr INR) relationships RPGAP • Partnership expected to yield benefits in terms of product selection, M&A, customer connects, cross-sell synergies and sharper focus on API amongst other positives • This shall enable RPGAP to lead the next stage of growth story and accelerate value creation Note: The above structure shall come into effect upon closing of the Investment and shareholders’ agreement dated 29th July 2026 C Acquisition of Actis Generics by RPGAP for enhancing Product Portfolio Actis Generics • Actis is a fully backward-integrated RPGLS Investor manufacturer of API and complex intermediates based out of Vizag (AP) • Manufacturing facility is in Visakha Pharma City 60% 40% which provides all the benefits of a specialized pharmaceutical production area • The manufacturing facility is running at close to RPGAP full capacity with possibility of expansion at site • Highly technical multi-step manufacturing processes with an established price competitive 100% position in key molecules (Consideration of ~80 Cr INR incl. NWC) • Anti-Diabetic and Cardiology focused product portfolio with increasingly growing demand • Established long-standing relations with Actis Generics marquee customers Note: The above structure shall come into effect upon closing of the Share Purchase Agreement dated 29th July 2026 D Acquisition of Raghava Life Sciences for enhancing Capacity and Product Portfolio Raghava Life Sciences RPGLS Investor • State-of-the-art manufacturing facility located close to Hyderabad spread over 9 Acres and a large installed capacity of 300 KL. 60% 40% • The facility is maintained impeccably with new block built over the past 3 years • Backward integration - API and intermediates RPGAP • Significant R&D spend over the last few years – Portfolio of 29 API molecules of which 22 are commercialized and 7 are under development Factory, • Secured WHO GMP, EU GMP; KDMF and CEP approvals 100% product (Slump Sale - Consideration • Revenue and cost synergy potential with Actis and portfolio, of ~ INR 135 Cr incl. NWC) RPGAP customer relationships • Transaction provides access to certain marquee customer relationships Raghava Life • Plant’s revenue potential of about 200 Cr INR at full Actis Generics utilization levels Sciences Note: The above structure shall come into effect upon closing of the Business Transfer Agreement dated 02nd Sep 2026 RPG Active Pharma – strategic readiness in all aspects for future growth • Niche products with strong • Partnered with pharma demand outlook focussed Investor • Stringent product selection • Sharper focus on API, criteria for high margin focus industry connects Product Partnership • R&D focus with new product • State-of-the art factories development and cost future ready installed capacity optimisation initiatives (increased by 4x) • Building deeper R&D • Backward integration and high expertise with dedicated R&D R&D Manufacturing level of process optimisation centre • Ability to leverage economies of scale • Sufficient liquidity to pursue • Long-standing customer organic and inorganic growth relationships • Zero debt company with prudent • Fast expanding customer base Capital Customers leverage runway with acquisitions • Onboarded CEO with deep industry expertise Talent • Highly qualified and experienced team, building further THANK YOU